July 20, 2025 a 09:31 am
Healthcare Stocks - Performance Analysis
📊 In the rapidly evolving healthcare sector, keeping abreast of stock performance is vital for making informed investment decisions. This analysis delves into the performance of leading healthcare stocks over various time frames, identifying top performers and underperformers. By scrutinizing these movements, investors can better gauge market dynamics and potential future trends.
Healthcare Stocks Performance One Week
| Stock | Performance (%) | Performance |
|---|---|---|
| JNJ | 4.44% | |
| ISRG | 1.29% | |
| AMGN | -0.12% | |
| ABBV | -1.60% | |
| LLY | -2.55% | |
| MRK | -4.09% | |
| TMO | -4.65% | |
| ABT | -6.11% | |
| UNH | -7.23% |
Healthcare Stocks Performance One Month
| Stock | Performance (%) | Performance |
|---|---|---|
| JNJ | 9.10% | |
| TMO | 4.44% | |
| ABBV | 2.32% | |
| AMGN | 2.27% | |
| LLY | 1.44% | |
| MRK | 1.35% | |
| ISRG | 1.96% | |
| UNH | -6.19% | |
| ABT | -6.69% |
Healthcare Stocks Performance Three Months
| Stock | Performance (%) | Performance |
|---|---|---|
| ABBV | 11.52% | |
| ISRG | 10.87% | |
| AMGN | 8.41% | |
| JNJ | 4.69% | |
| MRK | 3.80% | |
| TMO | -0.50% | |
| LLY | -3.81% | |
| ABT | -4.09% | |
| UNH | -36.95% |
Summary
✅ Over the past week, JNJ has emerged as the top performer, whereas UNH underperformed significantly. In the monthly analysis, JNJ maintained its strong position, highlighting its relative robustness. ABBV leads the three-month evaluation, showcasing strong momentum, while UNH has continuously lagged across all periods analyzed. The data suggests an imperative for investors to scrutinize sector and company-specific dynamics closely, especially focusing on those consistently outperforming, such as ABBV, to capitalize on emerging opportunities within the healthcare sector.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years